Analysis of the expression and prognostic value of MT1-MMP, β1-integrin and YAP1 in glioma

Abstract

Increased expression of membrane type 1-matrix metalloproteinase (<i>MT1-MMP</i>/<i>MMP14</i>) is associated with the development of many cancers. <i>MT1-MMP</i> may promote the entry of yes-associated protein1 (<i>YAP1</i>) into the nucleus by regulating the regulation of <i>β1-integrin</i>. The purpose of this study was to investigate the effects of <i>MT1-MMP</i>, <i>β1-integrin</i> and <i>YAP1</i> on the prognosis of gliomas. The expression of proteins was detected by bioinformatics and immunohistochemistry. The relationship between three proteins and clinicopathological parameters was analyzed by the <i>χ</i> ² test. Survival analysis was used to investigate the effects of three proteins on prognosis. The results showed that high expressions of <i>MT1-MMP</i>, <i>β1-integrin</i> and <i>YAP1</i> were found in glioblastoma (GBM) compared with lower-grade glioma (LGG). There was a significantly positive correlation between <i>MT1-MMP</i> and <i>β1-integrin</i> (<i>r</i> = 0.387), <i>MT1-MMP</i> and <i>YAP1</i> (<i>r</i> = 0.443), <i>β1-integrin</i> and <i>YAP1</i> (<i>r</i> = 0.348). Survival analysis showed that patients with overexpression of <i>MT1-MMP</i>, <i>β1-integrin</i> and <i>YAP1</i> had a worse prognosis. <i>YAP1</i> expression was the independent prognostic factor for progression-free survival (PFS). There was a statistical correlation between the expression of <i>MT1-MMP</i> and <i>YAP1</i> and isocitrate dehydrogenase 1 (<i>IDHl</i>) mutation. Thus, this study suggested that <i>MT1-MMP</i>, <i>β1-integrin</i> and <i>YAP1</i>, as tumor suppressors, are expected to be promising prognostic biomarkers and therapeutic targets for glioma patients.